Bayer HealthCare / News archive

News archive

Topic
Product
Date
2015-04-24

Bayer Submits Marketing Authorization for Radium-223 Dichloride to Treat Prostate Cancer with Bone Metastases in Japan #

Bayer HealthCare has submitted an application for marketing authorization to the Ministry of Health, Labour and Welfare (MHLW) in Japan for radium-223 dichloride (radium-223) solution for injection for the treatment of prostate cancer patients with bone metastases.   » more

2015-04-23
Bayer supports cancer biomarker research in Europe

Bayer supports cancer biomarker research in Europe

Bayer HealthCare and University Medical Center Hamburg-Eppendorf (UKE) are the main coordinators of the newly founded international consortium CANCER-ID to develop and validate novel blood-based biomarker technologies in cancer.   » more

2015-04-15

Bayer to Present New Data on Advancing Oncology Portfolio #

Bayer HealthCare (Bayer) will present latest preclinical and clinical data on oncolocgy compounds with new mechanism of action including several potent and selective small molecule inhibitors and an antibody-drug conjugate at the American Association for Cancer Research (AACR) 106th Annual Meeting, April 18-22, 2015, in Philadelphia, PA.   » more

2015-04-14
Bayer Expands Clinical Development Program for Novel PI3K Inhibitor Copanlisib in Non-Hodgkin’s Lymphoma

Bayer Expands Clinical Development Program for Novel PI3K Inhibitor Copanlisib in Non-Hodgkin’s Lymphoma #

Copanlisib is a novel intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-? and PI3K-? isoforms. The PI3K pathway is one of the most frequently altered pathways in cancer and the PI3K isoforms regulate many cellular functions, such as growth control, metabolism and transcription initiation.   » more

2015-04-13
Bayer’s Companion Vector-Borne Diseases Web Conference Advances “One Health” Approach

Bayer’s Companion Vector-Borne Diseases Web Conference Advances “One Health” Approach

Nearly half of the world’s population is infected with at least one type of vector-borne disease(i). These diseases are transmitted from parasites to animals and humans, and have a significant impact on public health and the global economy.   » more

2015-04-01
New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection

New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection #

In the study of neovascular wet age-related macular degeneration (wet AMD) in China, patients receiving aflibercept solution for intravitreal injection 2 milligrams (mg) achieved superiority in visual and anatomical endpoints compared to photodynamic therapy.   » more

2015-03-31
Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease

Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease

Cardiovascular genomics is an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery.   » more

2015-03-26
Bayer receives approval for Gadovist® (gadobutrol) injection in Japan

Bayer receives approval for Gadovist® (gadobutrol) injection in Japan #

Bayer HealthCare received approval in Japan for Gadovist® (gadobutrol) injection for use with magnetic resonance imaging (MRI). Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight. In Japan, there are more than 1.6 million MRI procedures conducted annually which are contrast-enhanced.   » more

2015-03-24

Bayer to present new preclinical, early clinical and epidemiological data on advancing portfolio in gynecological therapies #

Bayer HealthCare (Bayer) will present latest preclinical, early clinical and epidemiological data on its advancing gynecological therapies portfolio at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA.   » more

2015-03-23
Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases

Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases

In its 10th year, the Companion Vector-Borne Diseases (CVBD®) World Forum leads a global public health conversation on vector-borne diseases under the banner: “One Health: joining efforts for a healthier world”.   » more

2015-03-11

Bayer to Present Latest Clinical Data in the Area of Kidney Diseases #

Bayer HealthCare will present latest clinical data on development candidates in the area of kidney diseases at the World Congress of Nephrology (WCN), March 13-17, 2015, in Cape Town, South Africa. An oral and poster presentation will describe the results from the Phase IIb ARTS-DN study with finerenone for the treatment of patients with diabetic nephropathy.   » more

2015-03-11
Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU

Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU #

Bayer HealthCare has submitted an application for marketing authorization of aflibercept solution for intravitreal injection for the treatment of myopic choroidal neovascularization (myopic CNV) to the European Medicines Agency (EMA).   » more

2015-03-05

Phase III Trial of Regorafenib Shows Insufficient Patient Recruitment #

Bayer HealthCare today announced that it is suspending enrolment into a Phase III trial with regorafenib (Stivarga®) in colorectal cancer patients with resected liver metastases due to insufficient patient recruitment.   » more

2015-02-26
Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion

Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion #

Bayer HealthCare announced today that EYLEA® (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).   » more

2015-02-26
Bayer: strong business momentum continues and portfolio transformation underway

Bayer: strong business momentum continues and portfolio transformation underway

Bayer had a very successful year in 2014, both operationally and strategically. The company set new records for sales and for EBITDA before special items.   » more

2015-02-25
Bayer Thrombosis Research Award 2015 goes to Dr. Markus Bender

Bayer Thrombosis Research Award 2015 goes to Dr. Markus Bender

The second winner of the Bayer Thrombosis Research Award has been chosen: the Scientific Committee of the Bayer Science & Education Foundation has awarded the EUR 30,000 prize to Dr. Markus Bender in recognition of his work on Wiskott-Aldrich syndrome.   » more

2015-02-24

ASCO GU 2015 to Feature Latest Oncology Research from Bayer #

Bayer HealthCare announced today that new data from its oncology portfolio will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place February 26 – 28 in Orlando, FL (USA).   » more

2015-02-20
Adempas® Approved in Japan for the Treatment of Pulmonary Arterial Hypertension

Adempas® Approved in Japan for the Treatment of Pulmonary Arterial Hypertension #

Following the approval of Adempas in January 2014 for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery, Adempas is now the first drug approved in Japan to treat two forms of pulmonary hypertension (PH).   » more

2015-02-19
Olivier Brandicourt to leave Bayer HealthCare

Olivier Brandicourt to leave Bayer HealthCare

Effective March 31, 2015, Olivier Brandicourt (59), Chairman of the Board of Management of Bayer HealthCare AG and member of the Executive Council of Bayer AG, will leave the company to become new CEO of Sanofi as of April 2, 2015.   » more

2015-01-29

Bayer to Present New Hemophilia Treatment Data at EAHAD 2015 #

Bayer HealthCare announced today that new data on treatments for Hemophilia A will be presented at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders to be held 11-13 February, in Helsinki.   » more

2015-01-27
Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban Study in Patients with a recent Embolic Stroke of Undetermined Source

Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban Study in Patients with a recent Embolic Stroke of Undetermined Source #

Bayer HealthCare, in partnership with its development partner Janssen Research & Development, LLC, announced today a collaboration with the Population Health Research Institute (PHRI) and the Canadian Stroke Prevention Intervention Network (C-SPIN) to conduct the global Phase III NAVIGATE ESUS study.   » more

2015-01-23
Bayer Receives Recommendation for Approval for New Treatment Option with Aflibercept Solution for Injection in EU

Bayer Receives Recommendation for Approval for New Treatment Option with Aflibercept Solution for Injection in EU #

Bayer HealthCare today announced that aflibercept solution for injection into the eye has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the previously-approved indication of Macular Edema secondary to Central Retinal Vein Occlusion (CRVO).   » more

2015-01-20
European Label Update of Bayer’s Xarelto® Now Including Guidance for Use in Patients with Atrial Fibrillation Undergoing Cardioversion

European Label Update of Bayer’s Xarelto® Now Including Guidance for Use in Patients with Atrial Fibrillation Undergoing Cardioversion #

Bayer HealthCare today announced the inclusion of specific guidance for doctors treating patients with non-valvular atrial fibrillation (AF) undergoing cardioversion to the European Xarelto® (rivaroxaban) Product Information.   » more

2015-01-05
FDA approves Bayer’s Gadavist® (gadobutrol) injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age

FDA approves Bayer’s Gadavist® (gadobutrol) injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age #

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved Gadavist® (gadobutrol) injection for use with magnetic resonance imaging (MRI) in pediatric patients less than 2 years of age, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.   » more

2014-12-17
Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children

Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children #

Bayer HealthCare today announced that it has filed a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of hemophilia A in adults and children.   » more

2014-12-17
Bayer to divest equine assets to Merial

Bayer to divest equine assets to Merial

The deal is expected to close in the first quarter 2015 subject to customary conditions, including relevant merger control clearance.   » more

2014-12-09
Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River Blindness

Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River Blindness

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis).   » more

2014-12-04
Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children

Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children #

Bayer HealthCare today submitted an application for marketing authorization to the European Medicines Agency (EMA) for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of hemophilia A in children and adults.   » more

2014-12-01

Bayer to Present Latest Data on Its Hematology and Oncology Portfolio #

Bayer HealthCare will present latest data from its hematology and oncology portfolio at the American Society of Hematology (ASH) 56th Annual Meeting, December 6-9, 2014, in San Francisco, CA.   » more

2014-11-18
Bayer Receives Approval for EYLEA® in Diabetic Macular Edema in Japan

Bayer Receives Approval for EYLEA® in Diabetic Macular Edema in Japan #

Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of patients with diabetic macular edema (DME).   » more

You see the news 1 to 30 out of 348
1 2 3 4 5 6 7 8 9 10 Next >
Bayer HealthCare Links

RSS Feed
RSS Feed

http://press.healthcare.bayer.com/en/press/news/news-archive/index.php

Copyright © Bayer HealthCare AG